INDV Stock Forecast & Price Target

Indivior Pharmaceuticals has demonstrated a solid growth trajectory with approximately 171,500 patients receiving Sublocade treatment in the third quarter of 2025, reflecting an 8% increase year-over-year, along with a significant 11% rise in prescribers to roughly 8,568. The company has revised its guidance for worldwide Sublocade sales to $825 million-$845 million, indicating a robust annual growth rate of roughly 10% at the midpoint compared to previous estimates. Additionally, management anticipates continuing category expansion in the long-acting injectable OUD market, which supports projected peak sales potential of $1.5-$2.0 billion and a favorable long-term EBITDA compound annual growth rate.

Indivior Pharmaceuticals has significantly reduced its commercial support for Sublocade, now operating in only four countries, which poses challenges for revenue growth and market presence. A projected revenue decline of approximately 6.5% for 2026 indicates ongoing difficulties stemming from strategic portfolio simplifications undertaken in the previous year. Despite potential for improved EBITDA margins, the company's reliance on a singular product and reduced market footprint raises concerns about its long-term financial health and sustainability.